A plain language summary of the molecular changes in the tumors of people with BRAF V600E–mutant colorectal cancer in the BEACON study

Other authors

Institut Català de la Salut

[Kopetz S] University of Texas MD Anderson Cancer Center, Houston, TX, USA. [Murphy DA] Formerly Pfizer, La Jolla, CA, USA. [Pu J] Formerly Pfizer, New York, NY, USA. [Ciardiello F] University of Campania Luigi Vanvitelli, Naples, Italy. [Desai J] Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. [Van Cutsem E] University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium. [Tabernero J] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. University of Vic – Central University of Catalonia, Vic, Spain

Vall d'Hebron Barcelona Hospital Campus

Publication date

2025-07-08T10:52:11Z

2025-07-08T10:52:11Z

2025



Abstract

Colorectal cancer; Mutation


Càncer colorectal; Mutació


Cáncer colorrectal; Mutación


What is this summary about? This summary discusses the genetic and molecular changes in tumors of participants with BRAF V600E–mutant metastatic colorectal cancer who were treated with encorafenib plus cetuximab, with or without binimetinib, in the BEACON study. What were the results? Encorafenib plus cetuximab, with or without binimetinib, reduced the risk of participants dying compared with cetuximab plus chemotherapy, regardless of genetic or molecular colorectal cancer subtypes. The study also found genetic and molecular changes in the participants’ tumors during treatment that were associated with how long they lived. What do the results of the study mean? The types of genetic and molecular changes that occur during treatment in participants’ tumors can affect their response to treatment with BRAF and MEK inhibitors.


This manuscript was funded by Pfizer.

Document Type

Article


Published version

Language

English

Publisher

Taylor & Francis

Related items

Future Oncology;21(14)

https://doi.org/10.1080/14796694.2025.2498880

Recommended citation

This citation was generated automatically.

Rights

Attribution-NonCommercial-NoDerivatives 4.0 International

http://creativecommons.org/licenses/by-nc-nd/4.0/

This item appears in the following Collection(s)